Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palazestrant + Palbociclib in HR+ HER2- breast cancer
NCT05266105Phase 1Active, not recruiting
- Sponsor
- Olema Oncology
- Start
- Dec 2021
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of palazestrant in breast cancer (2 arms), sponsored by Olema Oncology. Primary endpoints: Dose Limiting Toxicities at 28 days, Adverse Events and Serious Adverse Events and 1 more. Started Dec 2021; status: active, not recruiting.
02
Drugs
palazestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05266105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05266105.